Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
äŒæ¥ã³ãŒãACLX
äŒç€ŸåArcellx Inc
äžå Žæ¥Feb 04, 2022
æé«çµå¶è²¬ä»»è
ãCEOãElghandour (Rami)
åŸæ¥å¡æ°163
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 04
æ¬ç€Ÿæåšå°800 Bridge Parkway
éœåžREDWOOD CITY
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94065
é»è©±çªå·12403270603
ãŠã§ããµã€ãhttps://www.arcellx.com/
äŒæ¥ã³ãŒãACLX
äžå Žæ¥Feb 04, 2022
æé«çµå¶è²¬ä»»è
ãCEOãElghandour (Rami)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã